Figure 3
DV is neuroprotective. (A and B) Mean ischemic lesion volumes measured from brain sections stained with TTC (PSD 1-3) or H&E (PSD 7 and 15) in WT mice treated with different doses of DV (A) or in WT and Pln -/-mice treated as indicated (B) (*P < 0.05, **P < 0.01, n = 15 per treatment group per PSD). Mean ischemic lesion volumes for WT and Pln -/-on PSD 1-3 are repeated from Figure 1E , as these volumes were obtained in the same experiments as the volumes obtained with DV treatment of WT and Pln -/-mice. (C) WT or Pln -/-mouse brain TTC staining at PSD 3, or WT H&E staining on PSD 15, after animals received i.p. PBS or DV injections (1 mg/kg). Yellow asterisks and red circles indicate ischemic lesions. PBS-treated WT and Pln -/-brain images are repeated here from those shown in Figure 1F , as they were obtained from the same experiments shown in that figure. (D) Cresyl violet, cleaved caspase-3, and TUNEL staining, with propidium iodide (PI) nuclear counterstain, in the peri-infarct area in WT mice treated with PBS or with DV. Scale bars: 5 μm (cresyl violet) and 10 μm (caspase-3 and TUNEL). Figure 5E (there labeled stroke PBS and stroke DV, 1 mg/kg), as these experiments were all performed in parallel using the same groups for comparison. (F) Von Willebrand factor immunohistochemistry (green) on PSD 5 from WT mice treated as labeled. Scale bar: 10 μm. Representative WT stroke + PBS and WT stroke + DV images are repeated here from the identically labeled images in Figure 8A , to ease their visual comparison with animals treated with α5 antibody or DV + α5 antibody. (G) Peri-infarct blood vessel quantification as labeled (*P < 0.05, **P < 0.01 compared with PBS + IgG on the same day, n = 20 images analyzed per animal, 10 animals per experimental condition). (H) Anti-VEGF Western blot analysis of mouse stroke hemispheres with internal GAPDH as control. (I) Optical density quantification of VEGF Western blot analysis as shown in H (**P < 0.01, n = 5 per experimental condition).
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